Clinical Scorecard: Impact of Anticoagulant Selection on Mortality in Initial Management of Noncancer Venous Thromboembolism: Analysis of Medicare Data from 2011 to 2018
At a Glance
Category
Detail
Condition
Noncancer Venous Thromboembolism (VTE)
Key Mechanisms
Anticoagulation with direct oral anticoagulants (DOACs) or warfarin to prevent VTE-related morbidity and mortality
Target Population
Medicare beneficiaries aged 65 years or older with incident noncancer VTE
Care Setting
Outpatient and inpatient settings within Medicare healthcare system
Key Highlights
Rivaroxaban associated with lower 6-month all-cause mortality compared to warfarin (HR=0.82; 95% CI, 0.76-0.90).
No significant mortality difference between apixaban and warfarin (HR=0.96; 95% CI, 0.87-1.07).
DOACs appear safe for patients with concomitant kidney or liver disease, with similar mortality risks across anticoagulants.
Guideline-Based Recommendations
Diagnosis
Identify VTE via inpatient or outpatient ICD codes with anticoagulant prescription within 31 days of diagnosis.
Management
Prefer DOACs (rivaroxaban or apixaban) over vitamin K antagonists (warfarin) for primary treatment of noncancer VTE.
Exercise caution and individualized decision-making for patients with renal insufficiency (creatinine clearance <30 mL/min) or moderate to severe liver disease.
Monitoring & Follow-up
Monitor patients for bleeding and adverse events during anticoagulant therapy, especially those with kidney or liver comorbidities.
Risks
Potential residual confounding in observational data; bleeding risks must be balanced against benefits.
Limited data on patients with severe renal or liver impairment; clinical judgment required.
Patient & Prescribing Data
Medicare beneficiaries aged ≥65 years with incident noncancer VTE
Rivaroxaban showed lower mortality risk compared to warfarin; apixaban had similar mortality risk to warfarin; DOACs are generally safe in patients with kidney or liver disease.
Clinical Best Practices
Use propensity score matching and active comparator designs in observational studies to reduce confounding.
Consider patient comorbidities such as kidney and liver disease when selecting anticoagulant therapy.
Follow updated clinical guidelines recommending DOACs over warfarin for most patients with noncancer VTE.
Recognize limitations of clinical trials and supplement with real-world evidence for broader patient populations.
Mayo Clinic Children's delivers comprehensive care for children with liver disease, from early evaluation and second opinions to advanced therapies and pediatric liver transplantation.
